In this study we demonstrate a new form of immunoregulation: engagement on CD4 + T cells of the complement regulator CD46 promoted the effector potential of T helper type 1 cells (T H 1 cells), but as interleukin 2 (IL-2) accumulated, it switched cells toward a regulatory phenotype, attenuating IL-2 production via the transcriptional regulator ICER/CREM and upregulating IL-10 after interaction of the CD46 tail with the serine-threonine kinase SPAK. Activated CD4 + T cells produced CD46 ligands, and blocking CD46 inhibited IL-10 production. Furthermore, CD4 + T cells in rheumatoid arthritis failed to switch, consequently producing excessive interferon-g (IFN-g). Finally, gd T cells, which rarely produce IL-10, expressed an alternative CD46 isoform and were unable to switch. Nonetheless, coengagement of T cell antigen receptor (TCR) gd and CD46 suppressed effector cytokine production, establishing that CD46 uses distinct mechanisms to regulate different T cell subsets during an immune response.
A r t i c l e s
The suppression of immune responses to self antigen is vital to the limitation of autoimmunity. Similarly, the timely contraction of T cell responses to infection is critical for protection against immuno pathologies arising from exuberant inflammation. The cytokine interleukin 10 (IL10) is critical in immunosuppression 1 , inhibiting production of the proinflammatory cytokines tumor necrosis factor and IL12 in macrophages and dendritic cells 1, 2 and suppressing the production of IL2 and interferonγ (IFNγ) by effector T cells 3 . Thus, Il10 −/− mice succumb to colitis because of their inability to regulate immune responses to gut flora 4 , and susceptibility to colitis has like wise been reported for human families carrying mutations in genes encoding IL10 receptor chains 5 . Moreover, whereas IL10 deficiency in mice accelerates clearance of infection with Toxoplasma gondii or Trypanosoma cruzi, such mice succumb to tissue damage caused by overproduction of proinflammatory cytokines 2, 6 .
IL10 can be produced by many cell types, including dendritic cells, macrophages, B cells and T cells, among which T helper type 2 (T H 2) cells and adaptive regulatory T cells (T reg cells), such as type 1 T reg cells (Tr1 cells), have been suggested to be chief sources 1, 7, 8 . However, uncertainty as to the nature of critical IL10producing cells in vivo, particularly in humans, has been fueled by the realization that under certain conditions, large amounts of IL10 can be secreted by some natural T reg cells 9 , IL17producing helper T cells 10 and T H 1 cells [11] [12] [13] [14] . Indeed, IL10producing T H 1 cells have sparked much interest because they seem to be key in regulating immune responses to certain infections [14] [15] [16] [17] and because their induction might be a mecha nism by which tolerance is induced in the presence of persistent (self) antigen 18 . Thus, there is particular interest in understanding what regulates IL10 production by T H 1 cells.
CD46 is a ubiquitously expressed human type I transmembrane glycoprotein originally identified as a complementregulatory protein.
Coengagement of the T cell antigen receptor (TCR) and CD46 on human CD4 + T cells induces substantial IL10 secretion, moderate IFNγ production and expression of granzyme B and perforin 19, 20 . Indeed, that phenotype, plus an IL10dependent, transcription factor Foxp3-independent ability to suppress bystander effector T cells, establishes the similarity of T cells activated with antibody to CD3 (antiCD3) and antiCD46 to Tr1 cells 21 . Moreover, both CD46 dependent induction of IL10 and generation of Tr1 cells are highly dependent on exogenous IL2 (refs.7,19,21) , which suggests that CD46 might naturally be a key factor in the switch of T H 1 cells to a Tr1like phenotype; however, this has not been investigated directly.
CD46 binds the opsonins C3b and C4b and functions as a cofactor in their proteolytic degradation by serine protease factor I (ref. 22 ). CD46 also functions as a receptor for several important human pathogens, such as Streptococcus pyogenes 23, 24 . Four isoforms of CD46 arise by alternative splicing 25 . All isoforms contain four conserved complement control repeats, followed by variant forms of a highly
Oglycosylated region (designated B and C), a transmembrane anchor, and one of two possible cytoplasmic domains, designated CYT1 and CYT2. Thus, the four commonly expressed CD46 isoforms are BC1 (denoting glycosylated regions B and C connected to CYT1), BC2, C1 and C2. Both CYT1 and CYT2 contain kinase substrates and are tyrosinephosphorylated after CD46 crosslinking of human CD4 + T cells 26 , which also activates the TCR adaptor proteins p120CBL, Lat 23 and Vav, the small GTPase Rac and the kinase Erk 24 , and additionally regulates expression of the receptor tyrosine kinase Flt3 and its ligand 27 . Thus CD46 activation has considerable intrinsic potential to regulate T cell function and has been reported as a T cell costimulator.
Notably, the interaction of T cells with antigenpresenting cells induces the secretion of complement proteins (such as C3, factor B and factor D) and the subsequent generation of complementactiva tion fragments [28] [29] [30] by both cell populations. Such a scenario might provide local ligands for CD46, thereby affecting cell fate. Indeed, CD46 crosslinking by C3b and C4b during TCR activation can induce Tr1like cells 19 . Likewise, the presence of S. pyogenes during TCR acti vation in vitro promotes IL10secreting Tr1like cells 31 . Nonetheless, cultures of Tr1like cells induced by CD46 engagement paradoxically also produce large amounts of IFNγ and have other features of T H 1 cells 32 , which again raises the question of whether CD46 engagement is critically involved in T H 1Tr1 switching 19 .
Although activation of conventional CD4 + T cells defines the adap tive response, it is now appreciated that unconventional T cells, of which γδ cells are a prototype, contribute substantially to the early phases of immune responses. Although such cells proliferate and show rapid and effusive effector function, little is known about how their potential to promote immunopathology is controlled. Indeed, there is no clear case for the existence of TCRγδ + Foxp3 + T reg cells under normal circumstances 33 and scant evidence for the induction of IL10 + Tr1like γδ cells. Given the potential of CD46mediated signals to induce IL10 in adaptive T cells, it would be relevant to examine whether or not γδ cells are responsive to CD46TCR costimulation as well.
Finally, we also considered the importance in vivo of CD46 mediated regulation of T cells by examining patients with inflamma tory disease. By further analyzing the CD46mediated signals that regulate cytokine production in human conventional and unconven tional T cells, we establish here that the IL2dependent coactivation of human CD4 + T cells by TCRCD46 was a powerful means by which to promote T H 1 cells and then to switch them to IL10 production. This pathway was absent from γδ T cells and was impaired in rheu matoid arthritis. At the same time, CD46 showed additional modes of immunosuppression, which permitted it to regulate an immune response across its temporal progression.
RESULTS
Regulation of IL-10 secretion by CD46 and IL-2 Although activation of purified human CD4 + T cells with stimula ting monoclonal antibody (mAb) to CD3 and mAb to CD46 in the presence of IL2 induces substantial IL10 secretion and confers a suppressive phenotype 19 , we found that T cells activated with anti CD3 and antiCD46 also produced large amounts of IFNγ 19 (Fig. 1a) . To better understand these seemingly paradoxical effects of CD46, we varied the strength of the activating signals during T cell acti vation (all experiments here used cells of human origin). Although changing the concentrations of the CD3 and CD46specific mAbs did not substantially affect IFNγ or IL10 secretion measured 72 h after activation (data not shown), IL10 production was regulated by exogenous IL2 (Fig. 1b) . Specifically, in a concentration of IL2 of 0.5 U/ml or less, activation with antiCD3 and antiCD46 induced more IFNγ secretion than that of T cells activated with either anti CD3 alone or with antiCD3 plus antiCD28. AntiCD3 and anti CD46 also induced transient expression of IL2, detectable at 24 h after activation in the absence of exogenous IL2 (Fig. 1c) . Increasing the concentration of IL2 above 5 U/ml did not further increase IFNγ production, but in IL2 concentrations of 5-10 U/ml, T cells obtained from various donors and activated with antiCD3 and antiCD46 all showed considerable IL10 secretion in addition to IFNγ, with IL10 production increasing with the amount of IL2 (Fig. 1b) . This was highly specific to IL10, as no conditions promoted the production of IL4, IL5 or IL17 (data not shown). CD46induced IFNγ peaked 24 h after activation and then steadily decreased, whereas IL10 was barely detectable before 24 h and peaked at 72 h (Fig. 1c) . Thus, CD46mediated IFNγ production preceded IL10 secretion even in cultures containing high concentrations of IL2 that are most condu cive to IL10 production.
Successive induction of IFN-g + and IL-10 + cells We next investigated the singlecell dynamics of the secretion of IFNγ and IL10 induced by antiCD3 and antiCD46. We activated puri fied CD4 + T cells with mAb to CD3 alone or in combination with mAb to CD28 plus mAb to CD46 in the presence of a neutralizing mAb to IL2, or either a low dose (5 U/ml) or high dose (50 U/ml) of IL2. We measured active cytokine secretion 36 h after activation (Fig. 1d) . Blockade of IL2 inhibited cytokine production under every condition analyzed. However, in the presence of IL2, activa tion with antiCD3 and antiCD46 or with antiCD3, antiCD28 and antiCD46 induced three discrete T cell populations with dis tinct secretion profiles: IFNγ + IL10 − cells, IFNγ + IL10 + cells and IFNγ − IL10 + cells (Fig. 1d) . Cultures with IL2 at a concentration of 5 U/ml contained greater frequencies of IFNγsecreting cells (17.4% ± 5.2% IFNγ + IL10 − and IFNγ + IL10 + cells in cultures activated with antiCD3 and antiCD46) than IL10producing T cells (12.0% ± 1.8% IFNγ + IL10 + and IFNγ − IL10 + cells), whereas IL2 at a concentra tion of 50 U/ml induced substantially more IL10 + cells (24.7% ± 5.8% IFNγ + IL10 + and IFNγ − IL10 + cells). In contrast, although cultures stimulated with antiCD3 and antiCD28 also contained all three T cell populations secreting IFNγ and IL10, there was no IL2 dependent change in the ratio of IFNγproducing T cells to IL10 + T cells, and the total number of IL10producing cells remained low even in high concentrations of IL2 (Fig. 1d) . Although these results (Fig. 1d ) reflect assays at 36 h, cellular cytokine staining at 12 h, 72 h and 90 h after stimulation also mirrored the results of our kinetic study reported above (Fig. 1c) : at 24 h, coactivation of cells with anti CD3 and antiCD46 promoted mostly IFNγ + IL10 − cells, even in high concentrations of IL2, with the peak of IL10producing cells arising subsequent to this. By 90 h, the overall number of cytokine secreting cells decreased substantially (data not shown).
We used purified CD4 + T cell populations that at minimum included naive and memory CD4 + T cells, as well as natural T reg cells, for the experiments described above. To exclude the possibility that the observed CD46elicited populations reflected selective reactiva tion and/or population expansion of one or more of these subsets, we applied antiCD3-antiCD46 activation protocols to highly purified naive CD4 + T cells (CD4 + CD45RA + CD45RO − CD127 − CCR7 − CD25 − ). As before, we detected IFNγ + IL10 − , IFNγ + IL10 + and IFNγ − IL10 + cells in the presence of high concentrations of IL2 for 36 h (Supplementary Fig. 1 ). However, activation of naive T cell cultures induced a lower frequency of IL10 + cells than IFNγ + cells (1.6% ± 0.7% versus 5.6% ± 1.9%; Supplementary Fig. 1) . Conversely, the use A r t i c l e s of antiCD3 and antiCD46 to restimulate naive cells previously acti vated and expanded with mAb to CD3 and mAb to CD46 substantially increased the proportion of both IFNγ + IL10 + and IFNγ − IL10 + T cells (Supplementary Fig. 1, right) . Moreover, the frequency of IFNγ + IL10 + cells and IFNγ − IL10 + cells was significantly increased by each additional restimulation with antiCD3 and antiCD46 (P < 0.01). Again, we detected no IL4 or IL5 in any of these cultures (data not shown). Secondary stimulation with antiCD3 and anti CD46 also increased IL10 production, albeit to a lesser extent, from T cells initially activated with antiCD3 alone (Supplementary Fig. 1,  left) . In short, the IL2dependent emergence over time of IL10 producing cells does not obviously reflect the selective response of a preexisting subset.
We then assessed the capacity of the various cell populations induced by antiCD3 and antiCD46 to regulate T cell activation. We activated CD4 + T cells through ligation of CD3 and CD46 and subsequently sorted them into IFNγ + IL10 − , IFNγ + IL10 + and IFNγ − IL10 + subsets, which we then cultured for 18 h in IL2 at a concentration of 1 U/ml. The supernatants of these three cell types continued to contain large amounts of IFNγ, approximately equal amounts of IFNγ and IL10, and large amounts of IL10 with negligible IFNγ, respectively (data not shown). When we cultured freshly purified CD4 + T cells in the presence of those supernatants together with immobilized crosslinking antiCD3 and antiCD28, their proliferation (measured at day 6) was substantially inhibited by the supernatants of the IFNγ + IL10 + cells induced by antiCD3 and antiCD46 and of the IFNγ − IL10 + T cells (Fig. 1e) . The inhibi tion was not elicited by supernatants of IFNγ + IL10 − T cells or by supernatants of T cells activated for 72 h by antiCD3 and antiCD28 (Fig. 1e) . IL10 upregulated by antiCD3 and antiCD46 is the main soluble mediator of this effect, as regulation was almost completely blocked by a neutralizing mAb to IL10.
CD46-induced IL10 originates in a T H 1 subset
To assess whether CD46induced IFNγ + IL10 + and IFNγ − IL10 + T cells originated from the IFNγ + IL10 − T H 1 cells that first arose or whether each cell population arose with different kinetics from sepa rate cell populations (Fig. 2a) , we undertook two sets of experiments. First we activated purified CD4 + T cells with antiCD3 and antiCD46 in a high concentration of IL2 in the presence of neutralizing mAb to IFNγ, a condition known to inhibit T H 1 development 8 . As expected, after 48 h we observed a significant decrease in the number of 
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Fresh media Supernatant + isotype Supernatant + α-IL- IFNγ + IL10 − T cells (from 14% ± 4% to 4% ± 2.5%; Fig. 2b ). However, this treatment also substantially decreased the percentage of anti CD46induced IFNγ + IL10 + cells (from 16% ± 2% to 2.5% ± 1.5%) and of IFNγ − IL10 + cells (from 18% ± 3% to 1.5% ± 0.5%). Thus, limiting T H 1 differentiation limited the IL10 switch. IL10 neutrali zation did not decrease the cell number of any of the T cell popu lations induced but instead slightly increased their representation (IFNγ + IL10 − cells, from 14% ± 4% to 17.5 ± 4%; IFNγ + IL10 + cells, from 16% ± 2% to 19.5% ± 6.5%; IFNγ − IL10 + cells, from 18% ± 3% to 18.5% ± 2.5%; Fig. 2b ). These data suggest at minimum that the continuous production of IL10 initially induced via antiCD3, antiCD46 and IL2mediated signals does not depend on positive feedback by IL10 itself.
Second, we activated purified CD4 + T cells with antiCD3 alone or with antiCD3 and antiCD46 in a low concentration of IL2 and iso lated the resulting IFNγ + IL10 − cells. When, after 4 d of population expansion, we restimulated the cells with antiCD3 and antiCD46, they produced a high frequency of IFNγ + IL10 + and IFNγ − IL10 + cells (Fig. 2c) . Together these two data sets suggest that antiCD46 induced IL10secreting T cells obligatorily derive from an initial T H 1 phase. In agreement with that, antiCD3-antiCD46-mediated reactivation of T H 1 cells primed through activation of naive T cells with antiCD3 and antiCD28 in the presence of IL12 and neutral izing mAb to IL4 (strong T H 1skewing conditions) also promoted IFNγ + IL10 + and IFNγ − IL10 + cells (data not shown).
Anti-CD3-and anti-CD46-induced IL-10 cells retain T H 1 markers T cell lineages are characterized by specific transcription factor expression and activation: T H 1 differentiation is accompanied by phosphorylation of STAT1 and STAT4 and expression of Tbet 34, 35 ; T H 2 cells require STAT6 activation and GATA3 expression 34, 35 ; and natural T reg cells are characterized by Foxp3 expression 9 . When we activated purified CD4 + T cells for 36 h with antiCD3 and antiCD46 in a high concentration of IL2, all resultant cells had a predomi nantly T H 1 profile ( Table 1) . In mice, IL10 secretion by T H 1 cells requires activation of the kinase Erk 18, 36 . Likewise, CD46dependent, TCRindependent induction of Erk1 and Erk2 in human CD4 + T cells has been reported 24 . All three T cell populations induced with antiCD46 contained large amounts of phosphorylated Erk1 and Erk2 ( Table 1) . Signaling through the IL2 receptor complex induces Janus kinase-mediated phosphorylation of STAT5. Consistent with the fact that antiCD46induced IL10 production is IL2 dependent, we detected phosphorylated STAT5 in IFNγ + IL10 − and IFNγ + IL10 + cells, although it was lower in IFNγ − IL10 + T cells, perhaps consistent with their limited proliferative capacity 19 (data not shown).
Regulation of IL-2 secretion by CD3-CD46 signals Drawing further parallels with T H 1 cells, we examined IL2 expres sion, as it is a T H 1 hallmark reportedly lost by T H 1 cells that have the ability to also secrete IL10 (refs. 18,36) . We had detected IL2 expres sion in CD4 + T cell cultures activated with antiCD3 and antiCD46 (Fig. 1c) , and when we examined them in greater detail, we found that >85% of IFNγ + cells actively secreted IL2 at 36 h after activation with antiCD3 and antiCD46 (Fig. 3a) , whereas this was true for <25% of 
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IL10secreting cells 19 (Fig. 3a) . Of those, 50-60% coexpressed IFNγ (data not shown). Thus, cells activated with antiCD3 and antiCD46 shared with T H 1 cells production of IL2 that ceased with induction of the IL10secreting state.
Genearray comparison of primary CD4 + T cells activated with antiCD3 and antiCD46 versus those activated with antiCD3 and antiC28 showed substantially more mRNA for the transcriptional regulators ICER and CREM (which both control IL2 transcription and cannot be distinguished in FACS analysis with the antibod ies used; thus, called 'ICER/CREM' here) in cells activated with antiCD46 (data not shown). Translocation of ICER/CREM to the nucleus attenuates transcription of the gene encoding IL2 (ref. 37) . Flow cytometry confirmed that ligation of CD3 and CD46 induced ICER/CREM protein in all three subsets (Fig. 3b and Table 1 ). Unexpectedly, expression was highest in IFNγ + IL10 − cells, which continued to express IL2 (Table 1) . However, immunoblot analysis of cytoplasmic and nuclear fractions showed consistent nuclear trans location of ICER/CREM only after 48 h of activation with antiCD3 and antiCD46 (Fig. 3c) or with antiCD3, antiCD28 and antiCD46 (data not shown), coincident with the appearance of IL10 in the culture medium (Fig. 1c) . Activation with antiCD3 alone or with antiCD3 and antiCD28 did not lead to measurable nuclear trans location of ICER/CREM at any time point (data not shown). To deter mine if ICER/CREM bound 'preferentially' to the IL2 promoter in IL10 + cells, we used chromatinimmunoprecipitation analysis, with an ICER/CREMspecific mAb, of IFNγ + IL10 − and IFNγ − IL10 + cells purified 36 h after activation with antiCD3 and antiCD46. IL2 promoter-specific DNA sequences were precipitated only from IL10 + cells and not from IFNγ + T cells (Fig. 3d) . Thus, activa tion with antiCD3 and antiCD46 induces considerable ICER/ CREM expression in T H 1 cells, but this is inactive in IFNγ + cells that continue to produce IL2. Instead, active nuclear translocation occurs 'preferentially' in IL10 + cells, consistent with their lower IL2 production. IL2 production is not attenuated secondarily via IL10 production, because neither IL10 neutralization during activation with antiCD3 and antiCD46 nor the addition of recombinant human IL10 during CD3-IL2 stimulation affected ICER/CREM transloca tion or IL2 production (data not shown).
CD46 CYT-1 domain promotes IL-10 via the kinase SPAK As outlined above, CD46 is commonly expressed as four isoforms with two possible cytoplasmic domains, CYT1 and CYT2 (ref. 25; Supplementary Fig. 2 ). To determine whether CYT1 or CYT2 affect IL10 switching differently, we generated Jurkat T cells stably express ing either the BC-CYT1 isoform (BC1) or BC-CYT2 isoform (BC2). Untransfected Jurkat cells expressed only the C2 isoform and did not produce IFNγ or IL10 after activation with antiCD3 and antiCD46 in the presence of IL2 (Fig. 4a and data not shown) . In contrast, this property was acquired by BC1transfected cells but, notably, not by BC2transfected cells (Fig. 4a) .
A yeast twohybrid screen identified the prolinealanine-rich serinethreonine kinase SPAK as an interaction partner with CYT1 and CYT2 (data not shown). SPAK is broadly expressed and has been linked to the regulation of mitogenactivated protein kinases and T cell activation 38, 39 . Immunoprecipitation confirmed that SPAK constitutively bound to CD46 in unstimulated primary CD4 + T cells (Fig. 4b) . Although activation with antiCD3 completely disrupted the CD46SPAK interaction within 15 min, this was partially pre served when CD46 was also engaged (Fig. 4b) . SPAK also immuno precipitated together with CD46 (but with neither CD3 nor CD28) in unstimulated Jurkat T cells (data not shown). When we knocked down SPAK expression in purified CD4 + T cells through the use of small interfering RNA (siRNA), the cells had a lower capacity to pro duce IL10 after activation with antiCD3 and antiCD46 (Fig. 4c) . Consistent with that finding, Jurkat cells stably transfected with SPAK responded to activation with antiCD3 and antiCD46 by producing IL10, whereas cells transfected with a 'kinasedead' SPAK mutant did not produce IL10 under any of the activation conditions tested (Fig. 4d) . In short, the induction of IL10 by antiCD46-antiCD3 activation of human T cells is attributable at least in part to a signal ing pathway from the CYT1-BC1 tail of CD46 via SPAK. That pro posal is supported by the finding that knockdown of SPAK protein (Supplementary Fig. 3a ) substantially decreased the previously observed CD46mediated hyperphosphorylation of Erk 23, 24, 32 , a key factor in IL10 upregulation in T cells 36 (Supplementary Fig. 3b) . The observation that SPAK silencing abrogated both antiCD3 and antiCD46induced phosphorylation of the kinase Jnk suggests that SPAK might also contribute to Jnk activation in a CD46independent pathway. In contrast, and as a specificity control, phosphorylation of the mitogenactivated kinase p38 in T cells activated with antiCD3 alone or with antiCD3 and antiCD46 remained largely unaffected by knockdown of SPAK protein (Supplementary Fig. 3b) .
Regulation of the effector phase of gd T cells by CD46
T cells expressing the TCR γchain variable region 9 and δchain vari able region 2 (V γ 9V δ 2 T cells), the main γδ T cell subset in human peripheral blood, are biased mainly toward a T H 1like phenotype, but the generation of Tr1like cells from these cells has not been convinc ingly demonstrated. If CD46 regulation is a chief means of induc ing Tr1like cells, we reasoned that the scarcity of IL10producing V γ 9V δ 2 T cells might be associated with differences in the CD46 pathway. Indeed, although V γ 9V δ 2 T cells expressed CD46, albeit in smaller amounts than did CD4 + T cells (Supplementary Fig. 4a ), these different subsets differed considerably in their expression pattern of CD46 variants. The BC2 isoform, which did not confer IL10 production in Jurkat transfectants stimulated with antiCD3 and antiCD46 (Fig. 4a) , was unequivocally the main isoform in V γ 9V δ 2 T cells, in contrast to the variable expression pattern commonly observed in CD4 + T cells 26 (Fig. 5a) . As expected, stimulation of peripheral blood mononuclear cells (PBMCs) from healthy donors with HMBPP (a V γ 9V δ 2 T cell-specific agonist) elicited negligible IL10 production, and this was not affected by CD46 costimulation, even in high concentrations of IL2 (Fig. 5b) . However, we noted slightly less IFNγ production (data not shown; discussed below), in contrast to the promotion of IFNγ by antiCD3 and antiCD46 in CD4 + T cells (Fig. 1a,b) .
To further investigate the more direct immunosuppressive role of CD46 described above, we stimulated PBMCs from three additional donors with HMBPP with or without IL2 and crosslinking of CD46. Again, antiCD46 did not induce IL10 (data not shown) but consist ently decreased production of IFNγ and secretion of tumor necrosis factor (Fig. 5c) . This effect was not due to antiCD46induced cell death, because the proportion of apoptotic (annexin V-positive) and necrotic (annexin V-positive and propidium iodide-positive) V γ 9V δ 2 T cells and the overall proportion of V γ 9V δ 2 T cells were each similar in PBMCs stimulated with HMBPP and IL2 in the pres ence or absence of antiCD46 (Supplementary Fig. 4b) . A direct immunosuppressive effect of CD46 on V γ 9V δ 2 cells was also evident in downregulation of CD25 (IL2 receptor αchain), especially in the absence of IL2, in contrast to the response of CD4 + T cells (Fig. 5d) . To preclude potential interfering effects of other subpopulations, we sorted V γ 9V δ 2 T cells (>95% pure) from two donors by flow cyto metry and stimulated the cells with HMBPP, and separately activated CD4 + T cells from the same donors with antiCD3 and antiCD28. Although costimulation with antiCD46 during these activation con ditions allowed us to detect IFNγ + IL10 + and IFNγ − IL10 + CD4 + T cells, we did not detect such subpopulations among V γ 9V δ 2 T cells (Fig. 5e) , and IFNγ production was again generally lower in high concentrations of IL2 (Fig. 5f) . Finally, we investigated the possibil ity that IL10 could be induced by restimulation of V γ 9V δ 2 T cells A r t i c l e s with antiCD46 (as observed for naive CD4 + T cells; Supplementary  Fig. 2 ). Thus, we obtained a polyclonal T cell line (>75% V γ 9V δ 2 + ) after incubating PBMCs with HMBPP and IL2 and stimulated it with HMBPP and/or IL2 and antiCD46. Again, antiCD46 decreased the secretion of both tumor necrosis factor and IFNγ ( Supplementary  Fig. 4c ) but could not induce substantial IL10 production (data not shown). Although these results confirm the finding that the BC1 isoform is needed to switch cells to IL10 producers, they also show that activation of the BC2 isoform of CD46 directly inhibits T H 1like responses by a principal subset of unconventional T cells linked to the early phases of immune responses. Thus, CD46 seems to use two distinct mechanisms to regulate the production of pro inflammatory cytokines.
Possible contribution of defective CD46 signals to autoimmunity
We obtained further evidence that CD46 actively regulates IL10 in human pathophysiology by comparing the responses of CD4 + T cells from three healthy donors and three adult patients with rheumatoid arthritis to activation with antiCD3 and antiCD46 in the presence of IL2 at a concentration of 25 U/ml. The baseline expression of CD3, CD46 and CD25 was similar among all T cell samples (data not shown), yet at 36 h after activation, cultures from patients with rheumatoid arthritis had higher percentages of IFNγ + IL10 − and IFNγ + IL10 + T cells but very few IFNγ − IL10 + T cells (Fig. 6a) . In addition, whereas the amount of IFNγ and IL10 in the super natants of T cells from healthy donors was roughly similar, T cells from patients with rheumatoid arthritis had tenfold or more greater production of IFNγ than IL10 (Fig. 6b) , and supernatants derived from these cells had no suppressive activity (data not shown). Because chronic inflammatory conditions such as rheumatoid arthritis are often attributed to inappropriate responses to persistent antigen, we examined cytokine expression after restimulating T cells with anti CD3 and antiCD46. Cultures of T cells from healthy donors showed more switching to the IFNγ − IL10 + state and contained approxi mately equal distributions of IFNγproducing T cells (IFNγ + IL10 − and IFNγ + IL10 + ) and IL10secreting T cells (IFNγ + IL10 + and IFNγ − IL10 + ; Fig. 6c) , with a ratio of 1:1 for IFNγ and IL10 secreted into the culture media (data not shown). In contrast, restimulated cultures from patients with rheumatoid arthritis lacked a substantial IFNγ − IL10 + population, with a diminution even in IFNγ + IL10 + cell frequencies relative to the cells' initial stimulation (Fig. 6c) . Thus, the ratio of IFNγ to IL10 in the culture media was ~20:1 at that point (data not shown). Notably, T cells from normal donors and patients with rheumatoid arthritis responded similarly to activation with antiCD3 and antiCD28 ( Supplementary Fig. 5a-c) and T H 1 and T H 2driving cytokines (Supplementary Fig. 5d ), which showed that the observed deregulation in the expression of IFNγ versus IL10 in rheumatoid arthritis relates to a defect in CD46 responsiveness.
To further investigate IL10 switching in arthritis, we isolated CD4 + T cells from the synovial fluid of both inflamed knee joints of a patient with juvenile arthritis. Of note, primary T cells from synovial fluid mostly had an activated CD25 hi CD45RO + phenotype, although expression of CD3 and CD46 was equivalent (data not shown). Similar to the results obtained with bloodderived CD4 + T cells from patients with rheumatoid arthritis, these synovial T cells did not switch to the IFNγ − IL10 + state after an initial stimulation with antiCD3 and antiCD46 (Fig. 6d) ; produced much more IFNγ than IL10 during population expansion (Fig. 6e) ; were mostly locked into the IFNγ + IL10 − state after restimulation (Fig. 6f) ; and secreted ~30 times more IFNγ than IL10 into the culture medium after restimulation (data not shown). These data suggest that the antiCD3-antiCD46-IL2-mediated switch of the proinflammatory IFNγ + (T H 1) phenotype to an immunoregulatory phenotype of secreting only IL10 is dysfunctional in patients with rheumatoid arthritis and juvenile arthritis. Moreover, the defect seems to lie mainly in the shutdown of IFNγ production, as IL10 secretion itself by T cells from patients with rheumatoid arthritis is induced almost normally after CD46 engagement.
IL-10 secretion driven by local complement production Evidence underpinning CD46 as a key regulatory axis was provided by the finding that highly purified (antigenpresenting cell-free) antiCD3activated CD4 + T cell cultures contained the CD46 ligand C3b (data not shown) and had considerable deposition of C3b onto their cell surfaces (Fig. 7a) . C3b generation was increased by costimulation with either antiCD28 or antiCD46. The prospect that this functionally engages CD46 was supported by the finding that small amounts of IL10 production induced by activation of CD4 + T cells with antiCD3 or with antiCD3 and antiCD28 was decreased to background production by the addition of soluble antiCD46 (Fig. 7b) . Accordingly, the presence of immobilized C3b increased IL10 production by cells activated with antiCD3 alone or with antiCD3 and antiCD28 (data not shown).
DISCUSSION
Irrefutable evidence of the importance of IL10 in suppressing immunopathology has now been extended to humans, in whom it has both biological and clinical implications 40 . As a result, there is much interest in IL10producing cells. This area of study has progressed from the idea of an IL10 lineage to one that embraces cells that switch to IL10 production from an earlier incarnation as IFNγproducing T H 1 cells. Cultures that coexpress IL10 and IFNγ have been docu mented [11] [12] [13] [14] , and such a switch would have the seeming advantage of inducing a regulatory cytokine and simultaneously suppress ing an effector cytokine based on recognition of the same antigen. Nonetheless, how such a switch might naturally occur, particularly in humans, has not been examined in detail before, to our knowledge 40 . The results presented in our study here make the case that human T H 1 cells are promoted by coengagement of the TCR and CD46 but that as environmental IL2 increases, as would be the case in a flourishing effector response, a switch to regulatory IL10 production occurs, concomitant with diminished endogenous IL2 production.
Attesting to the importance of the mechanism outlined above, we found it to be defective in patients with rheumatoid arthritis. Moreover, it is striking that this switching also did not function in the main subset of human γδcells that are known to express IL10 only very rarely 33 . AntiCD46induced IL10 production required expres sion of CYT1 of CD46; CYT1bearing isoforms were expressed in CD4 + T cells but were undetectable in γδ T cells. Together these find ings would be consistent with the idea that the CD46TCR activa tion regime is a chief means of peripheral IL10 induction tightly regulated by the expression patterns of the respective CD46 isoforms. Notably, the analysis of γδ cells did show an effect of CD46TCR coengagement: instead of switching to IL10 production, the cells showed substantial suppression of the secretion of IFNγ and tumor necrosis factor as well as a decrease in CD25 expression. These data permit us to propose that CD46 uses distinct mechanisms to reg ulate the immune response from its beginning to its close: in the early stages it may promote IFNγ in conventional T cells while con trolling the rapidly activated effector functions of unconventional T cells; in the later stages, it switches conventional T cells to T reg cells.
It is now widely acknowledged that the complement system func tions well beyond simple danger recognition and microbe clearance A r t i c l e s and participates actively in adaptive immune responses 41 . Two para digms regarding complement functions have renewed interest in this evolutionary old innate system: first, complement has a role not only in the induction of T cell responses but also in their contraction and thus consequently in immune homeostasis 20, 42, 43 ; second, the local production of complement components by immunocompetent cells participates decisively in shaping adaptive immune responses 31, 41, 44 . The latter observation, derived mostly from mouse models, is in agree ment with our observation that C3b was produced early after activa tion of human CD4 + T cells with antiCD3 and was increased after costimulation. Thus, our data allow us to suggest a model in which presentation of antigen and TCR engagement induces the subsequent generation of CD46 ligands, which provides a means for CD46 activa tion early during T cell activation. Such activated cells are now poised to integrate the third signal-high environmental concentrations of IL2, reflecting a successfully expanded T H 1 response-and switch appropriately into the T reg cell or contraction phase.
The scenario described above then raises a question about the hier archy of CD46 activation (specifically in relation to CD28 costimu lation) in IL10 induction by T H 1 cells. The complete inhibition of CD3CD28 costimulation-induced IL10 production by interference with 'intrinsic' CD46 activation suggests a dominant role for CD46 in IL10 expression by T H 1 cells. Moreover, such 'physiological' CD46 engagement through C3b or C4b produced by activated T cells might provide the molecular mechanisms by which IL10secreting Tr1 cells are induced in vitro by other groups. The generation of 'classic' adaptive IL10producing (and IFNγproducing) Tr1 cells in culture requires minimally repetitive activation with antiCD3 and antiCD28 (or exposure to dendritic cells) of CD4 + T cells in the presence of high IL2 concentrations 7, 45 , which are conditions conducive for CD46 engagement and CD46induced IL10 production.
Testing the idea that CD46 is important in regulating CD4 + and γδ T cell responses in a small animal model is hampered at present by the fact that rodents lack CD46 expression on somatic cells and that a murine molecule recapitulating CD46's role in TCR-IL2-dependent IL10 induction has not yet been identi fied 20 . A published study of humans, however, has connected sub stantially lower IL10 expression after CD46 activation of CD4 + T cells with multiple sclerosis 46 . Although the switch from the T H 1 to Tr1 state was not examined in that study 46 , low IL10 production by T cells from patients with multiple sclerosis correlate with an abnormal increase in CYT2 expression, consistent with our find ing that CYT1 was required for IL10 expression whereas CYT2 was inefficient in inducing this. Those data combine with our observation that T cells from patients with rheumatoid arthritis were unable to promote the CD46mediated T H 1Tr1 switch to link defects in this pathway in clinically important autoimmune and/or inflammatory conditions. We speculate that a high intrinsic signal threshold of T cells to switch from the T H 1 phenotype to the Tr1 phenotype after IL2dependent CD46 activation might be a risk factor for autoimmunity. Consistent with that, certain CD25 polymorphisms have been correlated with multiple sclerosis, rheu matoid arthritis and type 1 diabetes 47 . Conversely, a low intrinsic threshold for CD46-IL2-mediated IL10 production might protect from autoimmunity but possibly at the price of a greater risk of chronic infection.
Notably, the induction of IL10 from naive CD4 + T cells through TCR-CD46-IL2 activation required repetitive stimulation of cells. This is reminiscent of the observation that the toleranceinducing switch of T H 1 cells into an IL10 + IFNγ + state in mice requires persistence of (self) antigen 18 . Similarly, only continuous exposure of nonallergic beekeepers to high doses of bee venom induces the switch from IFNγsecreting T H 1 cells to IL10producing Tr1like cells indicated by a decrease in T cell-mediated cutaneous swelling 48 . After antigen withdrawal, bee venom-specific T cells again produce only large amounts of IFNγ and no IL10 after the first reactiva tion and switch to IL10 production only after repetitive stimulation. AntiCD46activated T H 1 or Tr1 cells followed a similar scheme: sorted IFNγ − IL10 + T cells switched back to initial IFNγ production after population expansion and restimulation (data not shown). These data are consistent with the idea that IL10secreting cells might not necessarily represent a lineage but instead represent the endpoint of a successful effector T cell response. Indeed, they comply with the facts that T H 1 cells, T H 2 cells and IL17producing helper T cells can produce IL10 and that so far no Tr1specific lineage marker has been identified. Consequently, organs such as the gut, skin and lungs, in which there is chronic interaction between the host and the environ ment, might provide a local milieu, through continuous stimulation, that locks T H 1 cells into a regulatory state, potentially explaining the abundance of IL10secreting Tr1 cells in these sites 49 .
Although such T cell plasticity ensures the important flexibility to respond to microenvironmental signals appropriately, it poses a con siderable obstacle in the therapeutic use of IL10secreting T H 1 sup pressor cells. Tr1 cells generated in a controlled in vitro environment might reacquire a proinflammatory T H 1 phenotype after injection into autoimmune or transplant patients. Identifying the molecular signature that characterizes the effector and regulatory phases of CD46induced T H 1 and Tr1 cells might provide a means for actively inducing and locking these cells into the desired functional state. The ability to identify specific signaling events required for IL10 induc tion in T H 1 cells (for example, the CD46-CYT1-mediated activa tion of SPAK, as well as the expression and nuclear translocation of ICER/CREM) could be a useful step in creating a platform to monitor and potentially manipulate these pathways in the future.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
